Akathisia Participant report · patients with an acute manic or mixed episode
Aripiprazole leads to higher akathisia Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 3.16 [2.25, 4.43]
2305 participants
High
Nausea · patients with an acute manic or mixed episode
Aripiprazole leads to higher nausea Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 1.5 [1.2, 1.88]
2305 participants
High
Depressive disorder according to DSM or ICD criteriaClinician diagnostic interview · patients with depressive disorders in children and adolescents
1 finding from 1 review
Suicide completionCompleted suicide rates · patients with depressive disorders in children and adolescents
1 finding from 1 review
Remission or response (as defined in trial) · patients with depressive disorders in children and adolescents
Second generation antidepressant probably leads to higher remission or response (as defined in trial) compared with placebo (by medication) (moderate certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with depressive disorders in children and adolescents
Second generation antidepressant may leads to higher suicide‐related outcome compared with placebo (by medication) (low certainty).
1 finding from 1 review
Depressive symptoms · patients with depressive disorders in children and adolescents
1 finding from 1 review
Number relapsed‐recurred · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication probably leads to lower number relapsed‐recurred compared with placebo (moderate certainty).
1 finding from 1 review
Suicide‐related behaviour · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication showed no clear difference in suicide‐related behaviours compared with placebo (low certainty).
1 finding from 1 review
Total number of drop‐outs · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication showed no clear difference in drop‐outs compared with placebo (moderate certainty).
1 finding from 1 review
Response to treatment at 8 weeks · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher response to treatment at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to any cause at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects (dropouts) · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to adverse effects at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Remission · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher remission rates at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Change in depressive symptoms · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole showed no clear difference in change in depressive symptoms at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: akathisia (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
Weight gain · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: weight gain (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review